HSA
PTGX icon

Hussman Strategic Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Hussman Strategic Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,500
Closed -$1.11M – 305
2026
Q1 		$1.11M Sell
10,500
-2,100
-17% -$186K 0.24% 182
2025
Q4 		$1.1M Sell
12,600
-8,400
-40% -$688K 0.27% 169
2025
Q3 		$1.4M Sell
21,000
-10,500
-33% -$597K 0.3% 152
2025
Q2 		$1.74M Sell
31,500
-21,000
-40% -$1.01M 0.4% 100
2025
Q1 		$2.54M Sell
52,500
-52,500
-50% -$2.2M 0.62% 49
2024
Q4 		$4.05M Buy
+105,000
New +$4.58M 1.2% 7

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hussman Strategic Advisors's PTGX Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 10,500 shares — an estimated $1.11M sold.

Hussman Strategic Advisors first reported a position in PTGX in Q4 2024 and held it in 6 quarters. The position peaked at $4.05M in Q4 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 10,500 Protagonist Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Hussman Strategic Advisors first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 6 quarters.
  • Hussman Strategic Advisors's Protagonist Therapeutics position peaked at $4.05M in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.